Newron Pharmaceuticals SpA (NWRN) - Financial and Strategic SWOT Analysis Review
November 2019
49
About the Report
About the Report
Newron Pharmaceuticals SpA (NWRN)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description-A detailed description of the company's operations and business divisions.
- Corporate strategy-Analyst's summarization of the company's business strategy.
- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.
- Company history-Progression of key events associated with the company.
- Major products and services-A list of major products, services and brands of the company.
- Key competitors-A list of key competitors to the company.
- Key employees-A list of the key executives of the company.
- Executive biographies-A brief summary of the executives' employment history.
- Key operational heads-A list of personnel heading key departments/functions.
- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Newron Pharmaceuticals SpA (Newron Pharmaceuticals) is a research-based biopharmaceutical company which focuses on the discovery, development and commercialization of novel therapeutic drugs for the treatment of central nervous system disorders and pain. The company's marketed product, Xadago (safinamide), is developed as an adjunctive therapy for any stage of Parkinson's disease. Newron's other products in pipeline include ralfinamide for neuropathic pain; sarizotan for Rett syndrome; and Evenamide (NW-3509) for the treatment of schizophrenia. The company has development and commercialization collaborations with Zambon and Meiji Seika Pharma Co Ltd. It operates along with its subsidiaries in the UK, Sweden, Switzerland and the US. Newron is headquartered in Bresso, Milan, Italy.
Newron Pharmaceuticals SpA Key Recent Developments
Sep 12,2019: Newron reports half-year 2019 results
Jun 28,2019: Newron receives first tranche from financing agreement with European Investment Bank (EIB)
Mar 05,2019: Newron announces 2018 financial results and provides outlook for 2019
Oct 30,2018: Investment plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m
Sep 13,2018: Newron reports half-year 2018 results
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Products
Products
Newron Pharmaceuticals SpA, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts
Companies
Silence Therapeutics Plc
Santhera Pharmaceuticals Holding AG
Pharming Group NV
Nanobiotix SA
Biotie Therapies Corp
Biofrontera AG
AC Immune SA
Table of Contents
Table of Contents
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1-About the Company
Newron Pharmaceuticals SpA-Key Facts
Newron Pharmaceuticals SpA-Key Employees
Newron Pharmaceuticals SpA-Key Employee Biographies
Newron Pharmaceuticals SpA-Major Products and Services
Newron Pharmaceuticals SpA-History
Newron Pharmaceuticals SpA-Company Statement
Newron Pharmaceuticals SpA-Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2-Company Analysis
Company Overview
Newron Pharmaceuticals SpA-Business Description
R&D Overview
Newron Pharmaceuticals SpA-Corporate Strategy
Newron Pharmaceuticals SpA-SWOT Analysis
SWOT Analysis-Overview
Newron Pharmaceuticals SpA-Strengths
Newron Pharmaceuticals SpA-Weaknesses
Newron Pharmaceuticals SpA-Opportunities
Newron Pharmaceuticals SpA-Threats
Newron Pharmaceuticals SpA-Key Competitors
Section 3-Company Financial Ratios
Financial Ratios-Capital Market Ratios
Financial Ratios-Annual Ratios
Performance Chart
Financial Performance
Financial Ratios-Interim Ratios
Financial Ratios-Ratio Charts
Section 4-Company's Lifesciences Financial Deals and Alliances
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Newron Pharmaceuticals SpA, Recent Deals Summary
Section 5-Company's Recent Developments
Sep 12, 2019: Newron reports half-year 2019 results
Jun 28, 2019: Newron receives first tranche from financing agreement with European Investment Bank (EIB)
Mar 05, 2019: Newron announces 2018 financial results and provides outlook for 2019
Oct 30, 2018: Investment plan for Europe: EIB backs Italian CNS drug developer Newron Pharmaceuticals with up to EUR 40m
Sep 13, 2018: Newron reports half-year 2018 results
Mar 27, 2018: Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018
Mar 01, 2018: Newron Announces 2017 Financial Results and Provides Outlook for 2018
Feb 13, 2018: Newron Supports Global Rare Disease Day 2018 and Rett Syndrome Studies
Section 6-Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Figure
List of Figures
Newron Pharmaceuticals SpA, Performance Chart (2014-2018)
Newron Pharmaceuticals SpA, Ratio Charts
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019
List of Table
List of Tables
Newron Pharmaceuticals SpA, Key Facts
Newron Pharmaceuticals SpA, Key Employees
Newron Pharmaceuticals SpA, Key Employee Biographies
Newron Pharmaceuticals SpA, Major Products and Services
Newron Pharmaceuticals SpA, History
Newron Pharmaceuticals SpA, Subsidiaries
Newron Pharmaceuticals SpA, Key Competitors
Newron Pharmaceuticals SpA, Ratios based on current share price
Newron Pharmaceuticals SpA, Annual Ratios
Newron Pharmaceuticals SpA, Annual Ratios (Cont...1)
Newron Pharmaceuticals SpA, Interim Ratios
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Newron Pharmaceuticals SpA, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Newron Pharmaceuticals SpA, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.